PEPG

PepGen Inc.'s stock price has experienced notable fluctuations in the past six months (April 2026 - October 2026), with a 1-year change of -51.1% and a 1-month change of -25.9%. Key events impacting the stock price include a "surprise" FDA hold on its muscular dystrophy drug program on March 4, 2026, and mixed Phase 2 data for FREEDOM2-DM1 on March 30, 2026, which led to a significant stock value drop. The company reported Q1 2026 financial results on May 11, 2026, and presented clinical data at the 15th International Myotonic Dystrophy Consortium on May 21, 2026. Craig Hallum initiated coverage with a "buy" rating on June 16, 2026. On August 6, 2026, PepGen reported Q2 2026 financial results, and the Data Safety Monitoring Board (DSMB) recommended advancing PGN-EDODM1 into the highest dose cohort in the Phase 2 FREEDOM2-DM1 study and approved dose escalation in the FREEDOM-OLE study. HC Wainwright reiterated a "buy" rating on September 9, 2026, while Weiss Ratings upgraded shares from "sell (e+)" to "sell (d-)" on September 22, 2026. Wall Street Zen downgraded PepGen from a "hold" to a "sell" rating on October 10, 2026.